MA41271A - Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7 - Google Patents
Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7Info
- Publication number
- MA41271A MA41271A MA041271A MA41271A MA41271A MA 41271 A MA41271 A MA 41271A MA 041271 A MA041271 A MA 041271A MA 41271 A MA41271 A MA 41271A MA 41271 A MA41271 A MA 41271A
- Authority
- MA
- Morocco
- Prior art keywords
- antisens
- oligonucleotides
- methods
- targeting smad7
- smad7
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- 101700026522 SMAD7 Proteins 0.000 title 1
- 102000049873 Smad7 Human genes 0.000 title 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462097012P | 2014-12-26 | 2014-12-26 | |
| US201562235269P | 2015-09-30 | 2015-09-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA41271A true MA41271A (fr) | 2017-10-31 |
Family
ID=56151259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA041271A MA41271A (fr) | 2014-12-26 | 2015-12-22 | Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20190112608A1 (fr) |
| EP (1) | EP3237018A4 (fr) |
| JP (1) | JP2018502107A (fr) |
| KR (1) | KR20170105529A (fr) |
| CN (1) | CN107405413A (fr) |
| AU (1) | AU2015371325A1 (fr) |
| BR (1) | BR112017013765A2 (fr) |
| CA (1) | CA2971583A1 (fr) |
| CL (1) | CL2017001701A1 (fr) |
| CO (1) | CO2017007383A2 (fr) |
| EA (1) | EA201791471A1 (fr) |
| EC (1) | ECSP17040003A (fr) |
| IL (1) | IL253023A0 (fr) |
| MA (1) | MA41271A (fr) |
| MX (1) | MX2017008462A (fr) |
| SG (1) | SG11201705179TA (fr) |
| WO (1) | WO2016105516A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170069262A (ko) | 2014-10-17 | 2017-06-20 | 노그라 파마 리미티드 | Smad7 안티센스 올리고뉴클레오티드로 대상체를 치료하기 위한 방법 및 조성물 |
| WO2017147276A1 (fr) | 2016-02-23 | 2017-08-31 | Celgene Corporation | Méthodes de traitement de la fibrose intestinale par inhibition de smad7 |
| WO2018111323A1 (fr) * | 2016-12-14 | 2018-06-21 | Progenity Inc. | Méthodes et dispositifs ingérables pour la libération régio-spécifique d'inhibiteurs de smad7 au niveau du site d'une maladie du tractus gastro-intestinal |
| EP3554345A1 (fr) | 2016-12-14 | 2019-10-23 | Progenity, Inc. | Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur de smad7 |
| SG11202010012PA (en) | 2018-05-09 | 2020-11-27 | Ionis Pharmaceuticals Inc | Compounds and methods for reducing fxi expression |
| TWI833770B (zh) | 2018-06-27 | 2024-03-01 | 美商Ionis製藥公司 | 用於減少 lrrk2 表現之化合物及方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4175101A (en) * | 2000-02-23 | 2001-09-03 | Univ California | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
| CA2486147A1 (fr) * | 2002-05-17 | 2003-11-27 | Protein Design Labs, Inc. | Traitement de la maladie de crohn ou du psoriasis a partir d'anticorps anti-interferon gamma |
| ITRM20030149A1 (it) * | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| WO2008031014A1 (fr) * | 2006-09-08 | 2008-03-13 | Ore Pharmaceuticals Inc. | Procédé pour réduire ou soulager une inflammation dans le tube digestif |
| PT2099446E (pt) * | 2006-11-17 | 2013-02-13 | Shire Dev Inc | Método de tratamento de doença inflamatória intestinal |
| EP2326315A1 (fr) * | 2008-08-18 | 2011-06-01 | Glaxo Group Limited | Traitement d'une maladie auto-immune à l'aide d'antagonistes de l'il-18 |
| SI3121280T1 (sl) * | 2008-11-13 | 2025-08-29 | Nogra Pharma Limited | Antismiselne sestave in postopki za njihovo izdelavo ter uporabo |
| TR201000680A2 (tr) * | 2010-01-29 | 2011-08-22 | B�Lg�� Mahmut | Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler |
| JP6389122B2 (ja) * | 2011-09-15 | 2018-09-12 | ノグラ ファーマ リミテッド | 抗ｓｍａｄ７治療に対する応答性をモニターするための方法 |
| CA2948411A1 (fr) * | 2014-05-09 | 2015-11-12 | Nogra Pharma Limited | Methodes de traitement d'une maladie inflammatoire chronique de l'intestin |
| JP2017537973A (ja) * | 2014-10-17 | 2017-12-21 | ノグラ ファーマ リミテッド | バイオマーカーレベルを使用してｓｍａｄ７アンチセンスオリゴヌクレオチドを投与するおよびモニタリングするための方法 |
| WO2015011694A2 (fr) * | 2014-10-17 | 2015-01-29 | Celgene Corporation | Isotopologues d'oligonucléotides antisens smad7 |
-
2015
- 2015-12-22 MA MA041271A patent/MA41271A/fr unknown
- 2015-12-23 JP JP2017534594A patent/JP2018502107A/ja active Pending
- 2015-12-23 CA CA2971583A patent/CA2971583A1/fr not_active Abandoned
- 2015-12-23 US US15/539,497 patent/US20190112608A1/en not_active Abandoned
- 2015-12-23 WO PCT/US2015/000269 patent/WO2016105516A1/fr not_active Ceased
- 2015-12-23 SG SG11201705179TA patent/SG11201705179TA/en unknown
- 2015-12-23 EA EA201791471A patent/EA201791471A1/ru unknown
- 2015-12-23 KR KR1020177020587A patent/KR20170105529A/ko not_active Withdrawn
- 2015-12-23 MX MX2017008462A patent/MX2017008462A/es unknown
- 2015-12-23 EP EP15873796.5A patent/EP3237018A4/fr not_active Ceased
- 2015-12-23 CN CN201580076967.0A patent/CN107405413A/zh active Pending
- 2015-12-23 BR BR112017013765A patent/BR112017013765A2/pt not_active IP Right Cessation
- 2015-12-23 AU AU2015371325A patent/AU2015371325A1/en not_active Abandoned
-
2017
- 2017-06-19 IL IL253023A patent/IL253023A0/en unknown
- 2017-06-23 CL CL2017001701A patent/CL2017001701A1/es unknown
- 2017-06-23 EC ECIEPI201740003A patent/ECSP17040003A/es unknown
- 2017-07-25 CO CONC2017/0007383A patent/CO2017007383A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018502107A (ja) | 2018-01-25 |
| US20190112608A1 (en) | 2019-04-18 |
| MX2017008462A (es) | 2018-02-26 |
| BR112017013765A2 (pt) | 2018-02-27 |
| IL253023A0 (en) | 2017-08-31 |
| CN107405413A (zh) | 2017-11-28 |
| EA201791471A1 (ru) | 2017-12-29 |
| WO2016105516A1 (fr) | 2016-06-30 |
| EP3237018A1 (fr) | 2017-11-01 |
| EP3237018A4 (fr) | 2018-07-11 |
| CL2017001701A1 (es) | 2018-04-06 |
| CA2971583A1 (fr) | 2016-06-30 |
| CO2017007383A2 (es) | 2018-01-05 |
| WO2016105516A8 (fr) | 2017-07-06 |
| AU2015371325A1 (en) | 2017-07-13 |
| SG11201705179TA (en) | 2017-07-28 |
| KR20170105529A (ko) | 2017-09-19 |
| ECSP17040003A (es) | 2017-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46481A (fr) | Compositions d'oligonucléotides et méthodes associées | |
| EP3324978A4 (fr) | Compositions d'oligonucléotides et méthodes associées | |
| PT3118311T (pt) | Ácido nucleico anti-sentido | |
| EP3224353C0 (fr) | Élimination ciblée de gènes bactériens | |
| MA45188A (fr) | Oligonucléotides, compositions et méthodes associées | |
| EP3328873A4 (fr) | Oligonucléotides ciblés | |
| IL250448B (en) | Modified double helix RNA materials | |
| EP3408391A4 (fr) | Oligonucléotides ramifiés | |
| EP3314027A4 (fr) | Oligonucléotides thérapeutiques | |
| PT3134506T (pt) | Métodos de purificação de rna mensageiro | |
| DK3351633T3 (da) | Antisense-nukleinsyre | |
| DK3200886T3 (da) | Spilsystem | |
| DK3262066T4 (da) | Genterapi | |
| MA39481A (fr) | Thérapies ciblées | |
| DK3107563T3 (da) | Glycomålrettede terapeutiske midler | |
| DK3231444T3 (da) | Ny behandling | |
| DK3149124T3 (da) | Anvendelse af lavmolekylære imid-holdige kvaternære ammoniumsalte | |
| MA46422A (fr) | Oligonucléotides modifiés et méthodes d'utilisation | |
| EP3409779A4 (fr) | Oligonucléotidique monocaténaire | |
| MA41642A (fr) | Variants de protoxine ii et méthodes d'utilisation | |
| MA41271A (fr) | Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7 | |
| EP3362578A4 (fr) | Méthodes d'évaluation génomique du bétail | |
| DK3133923T3 (da) | Aav-based gene therapy for multiple sclerosis | |
| IL249254A0 (en) | Gene expression system | |
| EP2953506A4 (fr) | Brosse cosmétique torsadée |